Escope Tech Co., Ltd. is a technology-driven company focusing on the diagnostic techniques for panvascular diseases including heart diseases and brain diseases. In 2017, the company was founded by the talents in the realm of clinical medicine, computer science and mechanical engineering. In the new era of medical diagnosis, data-driven technologies like deep learning and machine learning along with knowledge-driven technologies, such as computational medicine, computational aided engineering, digital twins, etc emerged as the cornerstones of computational medicine. Escope Tech is committed to creating a world-leading medical imaging and data analysis platform for cardiovascular and cerebrovascular diseases. With the help of artificial intelligence, imaging, machine vision, simulation science, data mining and other underlying technologies, the company has achieved fully upgrade of clinics from imaging morphological indicators to imaging functional indicators. At present, our product lines cover the clinical assessments of the following five main fields, which are coronary artery, cardiac/heart function, intracranial artery, cerebral/brain function and peripheral artery.
In June 2022, Escope Tech have reached strategic cooperation with Huayi Zhongcheng
In May 2021, the prospective clinical trail of CoroScope CT-FFR completed the enrollment of 332 cases
In July 2021, Tianjin branch of Escope Tech was founded
In November 2021, Escope Tech raised hundreds of millions (RMB) in round A+ financing
In May 2019, CoroScopeTM CT-FFR was certified by the Medical Device Quality Inspection Center of the State Food and Drug Administration
In June 2019, the first research conference was held
In August 2019, Escope Tech raised several million (RMB) in round A financing
In October 2019, the clinical registetion of CoroScopeTM CT-FFR was launched.
In November 2019, Escope Tech won the sixth prize with Beijing Anzhen Hospital in the 4th Science&Technology Innovation Competition
In December 2019, Escope Tech completed the standard of knowledge products.
In August 2018, Escope Tech raised RMB10 million in angel round financing
In December 2018, Beijing branch of Escope Tech was founded
In October 2017, Escope Tech was founded in Shenzhen, China
Dr. Ren Zhang is a cardiologist in Abilene, Texas and is affiliated with multiple hospitals in the area, including Hendrick Medical Center and Stephens Memorial Hospital-Breckenridge. He received his medical degree from Peking Union Medical College and has been in practice for more than 20 years.
Professor of Cardiovascular Medicine in University Medical Line, Medicine, Member of Cardiovascular Institute, Medical Director of Cardiovascular Health in Stanford Medicine, Senior Medical Director of International Medical Service in Stanford Medicine.
Xiang Qian, MD, PhD, is a Pain Management Physician and Clinical Associate Professor of Anesthesiology, Perioperative and Pain Medicine at Stanford University. He is also the inaugural Stanford Medicine Endowed Director.<br/> At Stanford, Dr. Qian developed many advanced surgical and interventional technologies for his patients, and he currently leads the CT-guided interventional pain program and is the recipient of Translational and Clinical Innovation Award at Stanford.
In the context of the rapid development of AI technologies and the exponential growth of hardware’s capabilities, clinical diagnosis has entered into a new era, which is more automated, more accurate and most importantly more accessible. Medical imaging generated by CT/MR/DSA/Echo, etc, accounts for more than 80% of all data stored in hospitals, yet have not emerged as an informative diagnostic basis as it should be. The main reason is quite simple - not all the informations from medical imagings can be detected or derived by human eyes.
In this context, Escope Tech was established in October 2017, dedicated to the development of functional imaging technologies and its applications on accurate diagnosis with more accessibility, especially in the field of cardiac and cerebral diseases. Escope‘s mission is to build a series of efficacious, efficient, economical and eminent image-based products, just like realistic medical scopes. We believe that diligence leads to success. On the road ahead, Escope Tech will strive to develop a comprehensive and systematic diagnostic platform for vascular diseases that can be adopted by the most hospitals worldwide.
We believe that AI technology based on big data can be used to obtain imaging diagnosis through deep learning more quickly and accurately, and we believe that AI will play an increasingly prominent role in cardiovascular imaging in the future. In addition, in view of the limitations of a single imaging technology, multiple imaging technologies are organically combined to give more play to their own technical advantages, and complement their own shortcomings, namely, the multimodality of cardiovascular imaging technology, which will provide more comprehensive and systematic information support for the diagnosis and treatment of vascular diseases. In short, intelligence, precision and multimodality will be an important direction for the future development of cardiovascular imaging technology. Escope Tech hopes to be a trustworthy imaging think tank for doctors and help the development of precision medicine in China!
